Things are looking better for the biotech industry in 2024 after a decent performance in 2023. The world is cautiously wading through an uncertain macroeconomic environment. This year is likely to bring more cheer for the industry as the Fed has given clear indication of multiple interest rate cuts. The majority of the biotech players do not generate enough revenues to fund their operations and are dependent on external funds. A company starts generating revenues following a successful FDA approval and the ...